Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 22.8% | (64.4%) | (61.9%) | (31.2%) | (18.8%) | (16.6%) | (22.6%) | (43.8%) | 86.7% | 26.5% | 15.5% | 20.5% | 22.1% | 22.6% | 32.8% | 21.3% | 31.8% | 54.2% | 20.9% | 16.3% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 16.2%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Regeneron Pharmaceuticals, Inc. have been 26.5% over the past three years, and 27.6% over the past five years.
As of today, Regeneron Pharmaceuticals, Inc.'s Return on Equity (ROE) is 16.2%, which is higher than industry median of (51.8%). It indicates that Regeneron Pharmaceuticals, Inc.'s Return on Equity (ROE) is Good.